Security record · archived quarter
CMPS
COMPASS Pathways plc · Healthcare · Biotechnology
6Tracked holders
n/aΔ holders
9.78MShares held
$59.07MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 59 | +9 | 28.72M | $406.32M | +13 | −5 |
| Q1 2026 | 52 | +2 | 25.39M | $140.32M | +6 | −4 |
| Q4 2025 | 49 | +2 | 17.79M | $122.72M | +2 | n/a |
| Q3 2025 | 11 | 0 | 9.36M | $53.63M | +1 | −1 |
| Q2 2025 | 8 | -1 | 4.28M | $11.98M | n/a | −1 |
| Q1 2025 | 8 | -1 | 5.73M | $16.40M | n/a | −1 |
| Q4 2024 | 9 | +1 | 7.15M | $27.03M | +1 | n/a |
| Q3 2024 | 7 | +1 | 11.59M | $73.00M | +1 | n/a |
| Q2 2024 | 6 | n/a | 9.78M | $59.07M | n/a | n/a |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 3.38M | n/a | $20.43M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Two Sigma Investments ✦ | 348.54K | n/a | $2.11M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 263.80K | n/a | $1.59M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 16.20K | n/a | $97,841 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 190 holders, 92.50M shares, $510.22M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API